Business Wire

CA-VISA-INC.

11.7.2024 22:08:28 CEST | Business Wire | Press release

Share
Visa Celebrates the Olympic & Paralympic Games Paris 2024 With Expanded Team Visa Roster and Ways for Fans to Engage

With the Opening Ceremony in Paris about two weeks away, Visa (NYSE: V), the Worldwide Payment Technology Partner of the Olympic and Paralympic Games, today announced its final roster of 147 Team Visa athletes for Paris 2024. Visa also shares ways to connect fans to the spirit of Paris 2024, both for those in attendance and those who want to participate at home.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711202801/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Team Visa Olympic and Paralympic Games Paris 2024 (Photo: Business Wire)

“As the Worldwide Payment Technology Partner of the Olympic and Paralympic Games, we’re excited to integrate Visa products and platforms that create value for both the athlete and fan experience during Paris 2024,” said Frank Cooper, CMO, Visa. “The Team Visa athletes preparing to compete in the Olympic and Paralympic Games Paris 2024 have consistently taken small steps over many years to reach this goal. We have supported these incredible athletes in their quest and want to help share their journeys with the world.”

Introducing Team Visa for Paris 2024

Founded in 2000, Team Visa has championed nearly 700 athletes over the last quarter century – each selected because of their athletic achievements, community involvement, and alignment with Visa’s core values of equality, access, and inclusion. Team Visa for Paris 2024 includes decorated Olympians and Paralympians like Simone Biles (USA, Gymnastics), Sky Brown (Great Britain, Skateboarding), Noah Lyles (USA, Athletics - Sprint) and Raissa Rocha Machado (Brazil, Para Athletics - Javelin) as well as first-timers like Shigeyuki Nakarai (Japan, Breaking) and Goodness Nwachukwu (Nigeria, Para Athletics - Discus). Team Visa also welcomes refugee athlete Dina Pouryounes (Taekwondo), forced to flee her homeland in the North of Iran to find refuge in The Netherlands.

“Visa has always been committed to empowering athletes on and off the track and it is great to see that in action,” said Noah Lyles. “I’m looking forward to getting in the blocks in Paris and putting it all out there. I have so much gratitude for my support system who has been with me every step of the way, including Team Visa.”

Team Visa by-the-numbers

  • 147 athletes representing 67 countries, 40 sports, including the new Breaking competition, making this Visa’s largest, most diverse roster yet, and with 46 Paralympic athletes and hopefuls, our largest Paralympic roster to date
  • 80 female and 67 male – underscoring Visa’s commitment to inclusion in sport
  • Record breakers and world #1s like Iga Świątek (Poland, Tennis), PV Sindhu (India, Badminton), and Simone Biles (USA, Gymnastics)
  • Newcomers and veterans alike, such as first-timers Qingyi Liu (China, Breaking) and Alexia Putellas (Spain, Football) and returners Kanoa Igarashi (Japan, Surfing) and Adam Peaty (Great Britain, Swimming)

Engaging fans in Paris and around the world

In the spirit of the theme “Pas Sans Vous,” or “Not Without You,” Visa is taking action to ensure everyone, everywhere can participate in Paris 2024:

  • Visa Go, a new mobile application for Visa cardholders visiting the Olympic and Paralympic Games Paris 2024, offers access to unique experiences and exclusive content, spotlights Team Visa athletes and shares their progress during Paris 2024. The app will also offer a curated selection of discounts and offers from official partners and local shops and restaurants. Fans can purchase a virtual Visa prepaid card through Visa Go, if needed.
  • Blending sports with culture, Visa has commissioned six global artists to create works of art to appear on billboards throughout Paris and other nearby host cities celebrating Paris 2024 and highlighting local commerce. In a tribute to Paris, the global capital for street art, pieces will appear on billboards in train stations, airports, the metro, and elsewhere around the cities to help support and promote local small businesses, who contribute to the city’s vitality. Participating artists include leading street artist from Seine-Saint-Denis Marko 93 (France); influential street artist and activist Swoon (USA); pioneering graffiti artist JonOne (USA); native Parisian artist Olivia De Bona (France); prolific colorblind street artist Alex Senna (Brazil); and multidisciplinary artist Vexta (Australia).
  • A custom payment services solution that Visa has implemented for Paris 2024 will bring seamless contactless payment acceptance to 3,500 points of sale across 32 Olympic venues and 16 Paralympic venues.
  • In recognition of Visa’s long-standing partnership with the Olympic and Paralympic Games, Paris 2024 proudly accepts only Visa for card and mobile payments, along with cash, at Olympic and Paralympic venues as well as the flagship Paris 2024 Megastore on Paris’ iconic Champs-Élysées and other official merchandise shops around France. Visa is also the Official Way to Pay for official merchandise online at the Olympic Shop.
  • Fans can join the fun on Roblox at Olympic World presented by Visa, a new immersive experience that features a unique collection of sports-themed activities, quests, and fun facts.

In the Paris metro area, “Pas Sans Vous” will come to life through Visa’s commitment to giving back to local youth and small business. Visa has partnered with youth sports program Sport Dans La Ville, providing hundreds of tickets to Paris 2024 for program participants, funding new sports centers and a girls mentorship program, as well as a development program for young journalists with Le Monde, one of France’s top news platforms. Additionally, Visa invited small businesses across France to participate in the “Les Paiements Gagnants,” or “Winning Payments” national promotion, in which more than 25,000 small businesses opted in to offer Visa cardholders a chance to win Paris 2024 tickets, helping small businesses to benefit more from the commercial opportunities that the Olympic and Paralympic Games bring.

Learn more about Visa’s commitment to the Olympic and Paralympic Games here.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240711202801/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye